These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 9664152)
1. Prognostic value of biomarkers in malignant melanoma. Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152 [TBL] [Abstract][Full Text] [Related]
2. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma. Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S Oncology; 2002; 62(3):259-68. PubMed ID: 12065874 [TBL] [Abstract][Full Text] [Related]
4. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773 [TBL] [Abstract][Full Text] [Related]
6. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864 [TBL] [Abstract][Full Text] [Related]
7. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578 [TBL] [Abstract][Full Text] [Related]
8. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Zirbes TK; Lorenzen J; Baldus SE; Moenig SP; Wolters U; Ottlik A; Thiele J; Hölscher AH; Dienes HP Histopathology; 1998 Aug; 33(2):123-8. PubMed ID: 9762544 [TBL] [Abstract][Full Text] [Related]
9. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Heino J; Pyrhönen S Melanoma Res; 2004 Feb; 14(1):29-37. PubMed ID: 15091191 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890 [TBL] [Abstract][Full Text] [Related]
11. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569 [TBL] [Abstract][Full Text] [Related]
13. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558 [TBL] [Abstract][Full Text] [Related]
14. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274 [TBL] [Abstract][Full Text] [Related]
15. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification. Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589 [TBL] [Abstract][Full Text] [Related]
19. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]